Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Head and neck cancer patients scheduled for definitive or postoperative chemoradiotherapy.~* Patients with a histopathological diagnosis of head and neck cancer and primary tumor in one of the following regions.~  1. Definitive therapy: nasopharynx, oropharynx, hypopharynx, or larynx~ 2. Postoperative therapy: oral cavity, oropharynx, hypopharynx, or larynx~* Patients with no history of chemotherapy, radiotherapy, or chemoradiotherapy for head and neck cancer~* Patients with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1~* Patients who are able to hold fluid in the mouth~* Patients who are able to swallow the investigational medicinal product (IMP)~* Patients expected to survive for at least 3 months~* Patients who have given written informed consent in person~* Patients who can stay at or visit the hospital for scheduled examinations and observations~* Patients who are able to take contraceptive measures to avoid pregnancy of the patient or their partner from the time of informed consent until 4 weeks after completion of IMP administration~Exclusion Criteria:~* Patients with primary malignant tumors other than head and neck cancer.~* Patients with symptomatic viral, bacterial, or fungal infection~* Patients with serious renal impairment~* Patients with distant metastasis~* Patients with severe complications (uncontrolled cardiac disease, diabetes, hypertension, etc)~* Patients with any of the following laboratory test results:~  1. Neutrophil count: \<1500 L~ 2. Platelet count: \<75000 L~ 3. Hemoglobin: \<10.0 g/L~ 4. Aspartate aminotransferase (AST): \>3 times the upper limit of the reference value at the trial site~ 5. Alanine aminotransferase (ALT): \>3 times the upper limit of the reference value at the trial site~ 6. Serum bilirubin: \>1.5 times the upper limit of the reference value at the trial site~ 7. Serum albumin: \<3.0 g/dL~ 8. Serum creatinine: \>1.5 the upper limit of the reference value at the trial site~ 9. Creatinine clearance : \<30 mL/min~* Patients complicated with autoimmune disease~* Patients requiring continuous systemic administration of glucocorticoid~* Female patients who are pregnant or lactating, who may possibly be pregnant, or who wish to become pregnant~* Patients who have participated in any other clinical trial within 4 weeks prior to initiation of chemoradiotherapy~* Patients who have a history of drug allergy to rebamipide, cisplatin, or other platinum compounds~* Patients who are otherwise judged by the investigator or sub-investigator to be inappropriate for inclusion in the trial

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 6 times daily
- 2% Rebamipide liquid (Type: EXPERIMENTAL): 6 times daily
- 4% Rebamipide liquid (Type: EXPERIMENTAL): 6 times daily

Based on this trial design, predict the completion outcome and termination type (if applicable).